Please assess the completion status of the following clinical trial:

Trial Title: Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* PD based on the United Kingdom Parkinson's Disease Society Brain Bank~* Diagnostic Research Criteria with or without Freezing of Gait~* Duration of Disease \> 5 years~* Mini-Mental State Examination (MMSE) \> 23~Exclusion Criteria:~* Dementia~* Dementia with Lewy Bodies~* Other disorders which may resemble PD~* Subjects on neuroleptic, anticholinergic (trihexyphenidyl, benztropine) or cholinesterase inhibitor drugs~* Evidence of a stroke or mass lesion on structural brain imaging (MRI)~* Participants in whom MRI is contraindicated including, but not limited to:~  * those with a pacemaker~ * presence of metallic fragments near the eyes or spinal cord~ * cochlear implant~* Severe claustrophobia precluding MR or PET imaging~* Subjects limited by participation in research procedures involving ionizing radiation~* Pregnancy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Parkinson's disease without FoG (Type: None): Subjects with Parkinson's disease that do not have freezing of gait observed during motor assessment while both on or off dopaminergic medication who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid).
- Parkinson's disease with FoG only while off-meds (Type: None): Subjects with Parkinson's disease that have freezing of gait observed during motor assessment only while off dopaminergic medication who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid).
- Parkinson's disease with FoG worse while off-meds (Type: None): Subjects with Parkinson's disease that have freezing of gait observed during motor assessment while both on and off dopaminergic medication, but greater severity of FoG under off-med, who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid).
- Parkinson's disease with FoG equivalent between on and off meds (Type: None): Subjects with Parkinson's disease that have freezing of gait observed during motor assessment while both on and off dopaminergic medication, with no apparent effect of dopaminergic medication on FoG, who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid).

Based on this trial design, predict the completion outcome and termination type (if applicable).